title: Evaluation of WO2013117503 and WO2013117504: the use of PI3K inhibitors to treat cough or idiopathic pulmonary fibrosis.
abstract: Two applications claim the use of the closely related, broad spectrum phosphatidylinositol 3-kinase inhibitors 2,4-difluoro-N-{2-(methoxy)-5-[4-(4-pyridazinyl)-6-quinolinyl]-3-pyridinyl}benzenesulfonamide (GSK-2126458) and 2,4-difluoro-N-{2-(methoxy)-5-[4-(4-morpholino)-6-quinazolinyl]-3-pyridinyl}benzenesulfonamide for the treatment of idiopathic pulmonary fibrosis and cough, respectively. Some in vitro data are presented in support of these claimed utilities. Since the filing of these applications, GSK-2126458 has commenced a dose-finding Phase I study in patients with idiopathic pulmonary fibrosis.
authors.affiliation: Norman Consulting , 18 Pink Lane, Burnham, Bucks, SL1 8JW , UK peter.norman2@btinternet.com.
authors.forename: Peter
authors.initials: P
authors.lastname: Norman
mesh_terms: D003371:Cough / Q000188:drug therapy*; D055808:Drug Discovery; D005347:Fibroblasts / Q000187:drug effects / Q000502:physiology; D006801:Humans; D010330:Patents as Topic; D000081082:Phosphoinositide-3 Kinase Inhibitors; D010766:Phosphorylation; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D051057:Proto-Oncogene Proteins c-akt / Q000378:metabolism; D011658:Pulmonary Fibrosis / Q000188:drug therapy*; D011724:Pyridazines; D011804:Quinolines / Q000138:chemical synthesis / Q000627:therapeutic use; D013449:Sulfonamides / Q000138:chemical synthesis / Q000627:therapeutic use; D000096926:Benzenesulfonamides
chemical_list: D000081082:Phosphoinositide-3 Kinase Inhibitors; D047428:Protein Kinase Inhibitors; D051057:Proto-Oncogene Proteins c-akt; D011724:Pyridazines; D011804:Quinolines; D013449:Sulfonamides; C561454:omipalisib; D000096926:Benzenesulfonamides
keywords: GSK-2126458; cough; idiopathic pulmonary fibrosis; mammalian target of rapamycin inhibitor; phosphatidylinositol 3-kinase inhibitor